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a  b  s  t  r  a  c  t
Peripheral  T-cell  lymphomas  (PTCLs)  tend  to be  aggressive  and  chemorefractory,  with  about  70% of
patients  developing  relapsed/refractory  disease.  Prior  to 2009,  chemotherapies  were  the only  options  for
relapsed/refractory  PTCL,  other  than hematopoietic  transplants.  However,  chemotherapy  only  improves
survival by  about  1 month  compared  with  palliation.  Four  drugs  are  now  approved  in the  US  to treat
relapsed/refractory  PTCL:  pralatrexate,  romidepsin,  belinostat,  and  brentuximab  vedotin  (for  systemic
anaplastic  large  cell  lymphoma  [sALCL]).  Response  rates  with  pralatrexate,  romidepsin,  and  belinostat
range  from  25  to 54%  in mixed  relapsed/refractory  PTCL  populations,  while  86% of  sALCL  patients  respondnaplastic large cell lymphoma
ngioimmunoblastic T-cell lymphoma
elinostat
rentuximab vedotin
eripheral T-cell lymphoma
ralatrexate
to  brentuximab  vedotin.  Here,  we  critically  evaluate  the  evidence  supporting  the  current  drug  treatment
of relapsed/refractory  PTCL,  and  look  to the future  to see how  the treatment  panorama  may change
with  the advent  of new  targeted  therapies,  some  of which  (e.g.,  alisertib  in  PTCL  and  mogamulizumab  in
CCR4-positive  adult  T-cell  leukemia/lymphoma)  are  already  in  phase  3 trials.
©  2016  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).omidepsin∗ Corresponding author. Fax: +39 0516364037.
E-mail address: pierluigi.zinzani@unibo.it (P.L. Zinzani).
1 A wholly owned subsidiary of Takeda Pharmaceutical Company Ltd.
ttp://dx.doi.org/10.1016/j.critrevonc.2015.12.016
040-8428/© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open
icenses/by-nc-nd/4.0/).1. Introduction
T-cell lymphomas (TCLs) represent a heterogeneous yet rare
group of non-Hodgkin lymphomas (NHLs). Such malignancies are
conventionally divided into two classes according to their origin:
peripheral TCLs (PTCLs), the most common class of TCL (Karlin and
 access article under the CC BY-NC-ND license (http://creativecommons.org/
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oifﬁer, 2014), which arise from clonal proliferation of mature post-
hymic T cells (Karlin and Coifﬁer, 2014; Dearden et al., 2015);
nd cutaneous TCLs (CTCLs), which arise from malignant clonal
ransformation of mature skin-homing and/or skin-resident T cells
Guenova et al., 2014).
PTCLs represent <15% of all NHLs (Karlin and Coifﬁer, 2014),
ith a prevalence that varies considerably according to geography,
ncluding a particularly high rate in East Asia due to viral (Epstein-
arr virus [EBV] and human T-cell leukemia virus-1 [HTLV-1])
ssociation (Reddy and Evens, 2014; Vose et al., 2008; Foss et al.,
011). In the United States, it is estimated that PTCL affects <1 in
00,000 people (Morton et al., 2006), with approximately 9500 new
ases diagnosed each year (Malik et al., 2010). Over recent years,
he incidence of PTCL appears to be increasing in both Western and
sian countries (Chihara et al., 2012; Sharaiha et al., 2012), probably
s a consequence of the aging population and improved diagnos-
ics. PTCLs are mainly diagnosed in the over-50s, but median age
t presentation can vary between subtypes (Lunning and Horwitz,
013). These malignancies also tend to be more common in men
han women (Lunning and Horwitz, 2013).
According to the 2008 World Health Organization (WHO) clas-
iﬁcation, PTCLs can be subdivided into three major subgroups
nodal, extranodal, and leukemic) and 14 distinct entities based
n clinical features and pathologic phenotype (Fig. 1) (Karlin and
oifﬁer, 2014; Foss et al., 2011). The most commonly encountered
TCL diagnoses, accounting for more than half of all cases, are
ast-growing nodal malignancies, such as PTCL-not otherwise spec-
ﬁed (PTCL-NOS; a group of lymphomas that do not ﬁt into any
f the other classiﬁcations of PTCL) (25.9%), angioimmunoblastic
-cell lymphoma (AITL) (18.5%; a PTCL subtype often associated
ith viral infection), and systemic anaplastic large cell lymphoma
sALCL) (12.1%), which can be subdivided into anaplastic lymphoma
inase (ALK)-positive (ALK+; 6.6%; a more indolent malignancy)
nd ALK-negative (ALK−; 5.5%; a rapidly progressing malignancy)
orms depending on the presence or absence of an abnormal form
f the ALK protein on the surface of malignant T cells (Karlin and
oifﬁer, 2014; Vose et al., 2008; Foss et al., 2011). Other subtypes of
TCL include extranodal natural killer (NK)/T-cell lymphoma, nasal
ype (NKTCL) (10.4%; a class of malignancies linked with EBV infec-
ion that is generally classiﬁed as a PTCL subtype despite some
eing derived from NK cells), adult T-cell leukemia/lymphoma
ATLL) (9.6%; a malignancy associated with HTLV-1 infection), and
nteropathy-associated T-cell lymphoma (EATL) (4.7%; a PTCL sub-
ype frequently, but not always associated with celiac disease)
Karlin and Coifﬁer, 2014; Vose et al., 2008; Lunning and Horwitz,
013).
The majority of PTCLs (except for ALK+ sALCL) tend to be
ggressive and chemorefractory, and many patients have a gloomy
rognosis, with 5-year survival rates in patients with PTCL-NOS
r AITL estimated at approximately 30% (Karlin and Coifﬁer,
014; Vose et al., 2008). The frontline treatment approach for
TCL, albeit transiently effective (Karlin and Coifﬁer, 2014), varies
etween diagnoses, but for most subtypes comprises combi-
ation chemotherapy (most commonly CHOP, CHEOP, or other
nthracycline-based multidrug regimens, such as EPOCH and
yperCVAD), with autologous stem cell transplantation (ASCT)
iven as consolidation for selected patients (but not in ALK+ sALCL
atients) (National Cancer Institute, 2015a; Dreyling et al., 2013).
nfortunately, most patients with TCLs who undergo induction
reatment (70%) will go on to develop relapsed and/or refractory
isease (Dreyling et al., 2013). These patients can be particularly
ifﬁcult to treat – median overall survival (OS) among non-
ransplanted, relapsed/refractory patients with PTCL is 5.5 months
Mak  et al., 2013) – although new advances in therapy, such
s molecularly targeted treatments that disrupt the underlying
echanisms of disease, and novel chemotherapeutic agents andogy/Hematology 99 (2016) 214–227 215
regimens that can overcome resistance to conventional chemother-
apy, are helping to improve outcomes.
In this paper, we  attempt to comprehensively review the cur-
rent treatment landscape for relapsed/refractory PTCL, focusing in
particular on the new and exciting clinical data on novel targeted
therapies and chemotherapy regimens. We  also look forward to the
future by exploring the potential of investigational therapies that
are in various stages of clinical development for PTCL.
2. Methodology
A literature search was undertaken to identify clinical studies
reporting efﬁcacy outcomes following conventional and investiga-
tional pharmacologic therapies in patients with relapsed and/or
refractory PTCL, deﬁned according to the WHO  2008 classiﬁca-
tion. MEDLINE (PubMed) was searched for studies published up
to February 6, 2015, and bibliographies of recent systematic and
treatment reviews (2011–14) were searched manually. Confer-
ence proceedings from the American Society of Clinical Oncology
(ASCO), American Society of Hematology (ASH), European Society
for Medical Oncology (ESMO), and European Hematology Associ-
ation (EHA) annual meetings (2013–14) were also interrogated.
‘Peripheral T-cell lymphoma’ and distinct WHO-deﬁned PTCL dis-
ease entities (Fig. 1) were used as search terms. Publication titles
and abstracts were screened to identify clinical studies of drug
therapies in relapsed and/or refractory PTCLs. There were no
restrictions regarding study design or treatment, although prospec-
tive trials were selected preferentially; frontline studies were
excluded. Despite no formal analysis, data were extracted on study
type, patients, diagnosis, prior treatments, and efﬁcacy outcomes
(response rates, duration of response, progression-free survival
[PFS], and OS).
3. Treatment of relapsed/refractory PTCL
The rarity of PTCL and the lack of randomized controlled trials
mean there is currently little consensus regarding optimal therapy
for the majority of PTCL entities. Historically, management strate-
gies for PTCL have been derived from studies of predominantly
B-cell NHL that only included small numbers of patients with PTCL.
Guideline recommendations for treatment are also often based
on small case series, phase 2 trials, and expert opinion (Dearden
et al., 2015; National Cancer Institute, 2015a; Dreyling et al., 2013).
Because it is difﬁcult to recruit patients, most clinical trials of new
agents and regimens in PTCL have enrolled patients with a range of
diagnoses, and very few studies have focused speciﬁcally on single
disease entities. Interpretation of data, particularly in older studies,
is also hampered by the historical lack of a uniform classiﬁcation,
potential misdiagnosis, and the use of different criteria to assess
anti-lymphoma response.
3.1. Conventional chemotherapy in relapsed/refractory PTCL
Until recently, conventional systemic chemotherapies remained
the only salvage options for patients with relapsed/refractory PTCL,
aside from ASCT or allogeneic stem cell transplantation (allo-SCT),
the discussion of which is beyond the scope of this review (fur-
ther information on the key role of hematopoietic transplantation
in treating relapsed/refractory PTCL is provided in a number of
recent reviews (Perrone et al., 2013; Perrone and Corradini, 2014;
Schmitz et al., 2014; Gkotzamanidou and Papadimitriou, 2014)).
Unfortunately, the data to support the use of chemotherapy is weak,
as it is frequently derived from retrospective studies and/or older
prospective studies in which patient diagnoses are unclear or not
speciﬁed, and sample sizes are limited.
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therwise speciﬁed.
Combination regimens that are sometimes used to treat younger
tter patients with relapsed/refractory PTCL, either as stan-
alone salvage treatment or as a bridge to ASCT or allo-SCT,
nclude (National Cancer Institute, 2015a): DHAP (dexametha-
one, cisplatin, and cytarabine) (Velasquez et al., 1988; Mey
t al., 2006); ESHAP (etoposide, methylprednisolone, cytarabine,
nd cisplatin) (Velasquez et al., 1994); dose-adjusted EPOCH
etoposide, prednisone, vincristine, cyclophosphamide, and dox-
rubicin) (Wilson et al., 1993); ICE (ifosfamide, carboplatin, and
toposide) (Zelenetz et al., 2003); MINE (mesna, ifosfamide,
itoxantrone, and etoposide) (Dincol et al., 2010; Mayer et al.,
999); and gemcitabine-based regimens, such as GDP (gemc-
tabine, dexamethasone, and cisplatin), GemOx (gemcitabine and
xaliplatin), GND (gemcitabine, vinorelbine, and doxorubicin),
nd GEM-P (gemcitabine, cis-platinum, and methylprednisolone)
Emmanouilides et al., 2004; Ng et al., 2005; Arkenau et al., 2007;
ópez et al., 2008; Dong et al., 2013; Park et al., 2015). With these
egimens, the overall response rate (ORR) rarely exceeds 50%, the
uration of response is short, and only a few patients achieve
 complete response (CR) (Dreyling et al., 2013). Furthermore, a
ecent retrospective study suggests that use of chemotherapy regi-
ens following relapse or progression on frontline therapy in PTCL
atients (with PTCL-NOS, sALCL, or AITL) only improves median OS
y 1 month compared with no active treatment (Mak  et al., 2013).
For single-agent use in older and more vulnerable patients,
ncluding those with relapsed/refractory NKTCL, gemcitabine
ppears to be one of the most commonly used and most active
hemotherapies (Zinzani et al., 1998; Sallah et al., 2001; Zinzani
t al., 2000, 2010; Ahn et al., 2013). Originally used because of its
ctivity in CTCL (Zinzani et al., 2000), single-agent gemcitabine has
hown evidence of activity in PTCL, including a 55% ORR and 30%
R rate in patients with PTCL-NOS (Zinzani et al., 2010).
In terms of speciﬁc PTCL entities, single-agent cyclosporine may
eneﬁt patients with relapsed/refractory AITL, although the evi-
ence supporting its use is limited to case series and case reports
Advani et al., 2007). There is more evidence to support the useheral T-cell lymphomas (Swerdlow et al., 2008).
 lymphoproliferative disorders; TCL, T-cell lymphoma; NK, natural killer; NOS, not
of the intensive SMILE regimen (dexamethasone, methotrexate,
ifosfamide, l-asparaginase/pegaspargase, and etoposide) and its
various modiﬁcations, all of which contain l-asparaginase or pegas-
pargase as the key component, to treat relapsed/refractory patients
with extranodal NKTCL, nasal type (Yamaguchi et al., 2008, 2011;
Kwong et al., 2012; Jaccard et al., 2011). These regimens are asso-
ciated with high ORRs (>60%), but tolerability is an issue for many
patients due to the high risk of hematologic toxicity, nephrotoxicity,
hepatotoxicity, and infection (Yamaguchi et al., 2011; Kwong et al.,
2012). Nevertheless, l-asparaginase/pegaspargase-containing reg-
imens are now recommended as the mainstay of therapy for this
rare and difﬁcult-to-treat PTCL subtype (National Cancer Institute.,
2015a).
3.2. Approved therapies in relapsed/refractory PTCL
While conventional chemotherapies remain important thera-
peutic options in this setting, four next-generation drugs have
recently been approved in the United States, speciﬁcally for use
in patients with relapsed and/or refractory PTCL (Table 1). The ﬁrst
of these compounds is pralatrexate, an intravenous (IV) antifolate
chemotherapy with high afﬁnity for the reduced folate carrier-1
receptor and folypolyglutamate synthase, which exhibits greater
cytotoxic potency than either of the ﬁrst-generation antifolates,
methotrexate or edatrexate (Wang et al., 2003; Sirotnak et al., 1998;
Shimanovsky and Dasanu, 2013). This agent acts to inhibit dihy-
drofolate reductase and thymidylate synthase, and thereby disrupt
the DNA/RNA synthesis required for lymphoma cell proliferation
(Sirotnak et al., 1998; Shimanovsky and Dasanu, 2013). Pralatrex-
ate is currently indicated for the treatment of patients with relapsed
or refractory PTCL (FOLOTYN®, 2012). The second approved agent
is romidepsin, a potent IV class 1 histone deacetylase (HDAC)
inhibitor that acts to prevent gene transcription and disrupt pro-
tein function in malignant lymphoma cells by interfering with the
acetylation pattern of chromatin on histone lysine residues (Khot
et al., 2013a). Romidepsin is approved for the treatment of PTCL in
P.L.
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Table 1
Summary of prospective clinical trials for approved (belinostat, brentuximab vedotin, pralatrexate, and romidepsin) and investigational/off-label agents and regimens in relapsed/refractory peripheral T-cell lymphoma.
Agent/regimen and
reference
Phase N PTCL diagnoses Median
prior
therapies
(range)
Central
response
review
ORR (%) CR/CRu rate (%) Median DoR,
months
(range/95% CI)
Median
PFS,
months
Median OS,
months
Belinostat
(Foss et al., 2015) 2 24 PTCL-NOS n = 13 3 (1–9) No 25 8 3.6 (1.8, 4.2) 1.4a NR
AITL  n = 3
ALCL n = 3
ENKTCL n = 1
NKTCL n = 2
PTCL, skin n = 1
SPTCL n = 1
(O’Connor et al., 2015) 2 129 PTCL-NOS n = 177 2 (1–8) Yes 26 11 13.6 (4.5, 29.4) 1.6 7.9
(Horwitz et al., 2013) AITL n = 22 AITL: 2
(1–5)
PTCL-NOS: 23 AITL: 18 AITL: 7.5
(1.6–29.4)
AITL: 5.8 AITL: 9.2
ALK−  ALCL n = 13 AITL: 46
ALK+ ALCL n = 2 ALK− ALCL: 15
EATL n = 2 ALK+ ALCL: 0
ENKTCL n = 2 EATL: 0
HSTCL n = 2 ENKTCL: 50
HSTCL: 0
Brentuximab vedotin
(Pro et al., 2012) 2 58 sALCL n = 58 2 (1–6) Yes 86 59 13.2 (5.7, 26.3) 20.0 Not
reached
(Pro et al., 2013) (1 year:
70%, 3 year:
63%, 4
year: 64%)
(Pro et al., 2014)
(Ogura et al., 2014a) 1/2 5 sALCL n = 5 3 (1–6) Yes 100 80 9.7 10.8 NR
(Bartlett et al., 2014) 2 8 sALCL n = 8 3 (2–6) No 88 63 12.3 (6.6,
28.0+)
12.9 Not
reached
(Horwitz et al., 2014a) 2 35 PTCL-NOS n = 22 2 (1–9) No 41 24 7.6 (1.3–14+) 2.6 NR
AITL  n = 13 PTCL-NOS: 33 PTCL-NOS: 14 PTCL-NOS: 7.6 PTCL-NOS:
1.6
AITL: 54 AITL: 38 AITL: 5.5 AITL: 6.7
Pralatrexate
(O’Connor et al., 2009) 2/1/2 30 TCL n = 30c NR No 54 31 NR NR NR
(O’Connor et al., 2011) 2 111 PTCL-NOS n = 59 3 (1–12) Yes 29 11 10.1 (<1–22.1) 3.5 14.5
sALCL  n = 17 PTCL-NOS: 32
AITL n = 13 sALCL: 35
tMF  n = 12 AITL: 8
Other PTCL n = 10 tMF: 25
Other PTCL: 38
Romidepsin
(Coifﬁer et al., 2012) 2 130 PTCL-NOS n = 69 2 (1–8) Yes 25 15 28 (<1–48+) 4 11.3
(Coifﬁer et al., 2014) AITL n = 27 PTCL-NOS: 29 PTCL-NOS: 14
ALK−  ALCL n = 21 AITL: 30 AITL: 19
Other PTCL n = 13 ALK− ALCL: 24 ALK− ALCL: 19
Other PTCL: 0 Other PTCL: 0
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Summary of prospective clinical trials for approved (belinostat, brentuximab vedotin, pralatrexate, and romidepsin) and investigational/off-label agents and regimens in relapsed/refractory peripheral T-cell lymphoma.
Agent/regimen and
reference
Phase N PTCL diagnoses Median
prior
therapies
(range)
Central
response
review
ORR (%) CR/CRu rate (%) Median DoR,
months
(range/95% CI)
Median
PFS,
months
Median OS,
months
(Piekarz et al., 2011) 2 47 PTCL-NOS n = 27 3 (1–11) No 38 18 8.9 (2–74) NR NR
AITL  n = 7 PTCL-NOS: 41 PTCL-NOS: 19
ALK+  ALCL n = 2 AITL: 17
ALK−  ALCL n = 2 ALK− ALCL: 100
Other PTCL n = 9
Alemtuzumab monotherapy
(Enblad et al., 2004) 2 14 PTCL-NOS n = 10 2 (1–4) No 36 21 NR NR NR
AITL  n = 2
Angio-TCL n = 2
(Zinzani et al., 2005) 2 6 PTCL-NOS n = 6 3 (2–4)d No 50 33 7 (2–10)d NR NR
Alemtuzumab + pentostatin
(Ravandi et al., 2009) 2 16 PTCL-NOS n = 3 2 (1–6) No 50 43 NR NR NR
T-ALL  n = 2
T-PLL n = 8
Other n = 3
Alemtuzumab + FCD
(Weidmann et al.,
2010)
2 11 PTCL-NOS n = 4 NR No 55 27 NR 2.5 6.1
AITL  n = 5
ALK− ALCL n = 1
NK lymphoma n = 1
Alemtuzumab + DHAP
(Kim et al., 2009) 2 16 PTCL-NOS n = 7 NR No 50 25 NR NR 6.0
ENKTCL n = 7 PTCL-NOS: 86 PTCL-NOS: 43
AITL  n = 1 ENKTCL: 14
ALCL n = 1
Alisertib
(Friedberg et al., 2014) 2 8 PTCL n = 8 NR No 50 NR NR NR NR
(Barr et al., 2015) 2 37 PTCL-NOS n = 13 3 (1–18) No 24 5 3 (1–18) 3 8
AITL  n = 9 PTCL subtypes
excluding tMF: 30
PTCL subtypes
excluding tMF:
7
tMF  n = 7 tMF: 0 tMF: 0
ATLL n = 4 PTCL-NOS: 31 PTCL-NOS: 8
ALCL  n = 2 AITL: 33 AITL: 0
ENKTCL n = 2 ATLL: 25 ATLL: 25
ALCL: 50 ALCL: 0
ENKTCL: 0 ENKTCL: 0
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Bendamustine
(Damaj et al., 2013) 2 58 AITL n = 32 1 (1–3) No 50e 28e 3.5 (1–21)e 3.6e 6.3e
PTCL-NOS n = 23
ALCL (n = 2)
EATL (n = 1)
Bortezomib + gemcitabine
(Evens et al., 2013) 1/2 16 PTCL-NOS n = 12 3 (2–5)f No 36 27 NR NR NR
AITL  n = 1 (50 on modiﬁed
schedule)
NKTCL n = 1
tMF  n = 1
HSTCL n = 1
Crizotinib
(Mossé et al., 2013) 1 9 ALK+ ALCL n = 9 NR Yes 89 78 NR NR NR
Pediatric study
(Redaelli et al., 2013) 2 9 ALK+ ALCL n = 9 NR NR 100 100 10 (2–37) Not
reached
Not
reached
(3 year:
62%)g
(3 year:
73%)g
(Gambacorti-Passerini
et al., 2013)
1b 14 ALK+ ALCL n = 14 2 (1–6)h NR 60h 36h NR NR NR
Denileukin diftitox
(Dang et al., 2007) 2 27 PTCL-NOS n = 19 NR (1–6)i No 48i 22i NR 6i NR
AITL  n = 3 CD25+: 62 CD25+: 31
ALK−  ALCL n = 2 CD25−: 45 CD25−:  18
Other PTCL n = 2 PTCL-NOS: 42 PTCL-NOS: 21
Duvelisib (IPI-145)
(Horwitz et al., 2014b) 1 16 PTCL n = 16 4 (1–11)j No 47 13 NR NR 8.4
Forodesine (BCX1777)
(Ogura et al., 2012) 1 9 PTCL-NOS n = 6 2 (1–8)k No 11 11 NR NR NR
ALK−  ALCL n = 3 PTCL-NOS: 0 PTCL-NOS: 0
BreakTable ALK− ALCL:
33
ALK− ALCL: 33
Lenalidomide monotherapy
(Dueck et al., 2010) 2 39l PTCL-NOS n = 14 1 (0–5)l No 26l 8 13 (2–37+)l 4l 12l
(Toumishey et al.,
2015)
AITL n = 9 R/R: 24 R/R: 5 (2–37+) R/R: 4
ALCL  n = 10 ALCL: 10
EATL n = 2 AITL: 33
HSTCL n = 2 PTCL-NOS: 43
Lymphoblastic TCL
n = 2
(Zinzani et al., 2011) 2 10 PTCL-NOS n = 10 4 (2–7) No 30 30 NR (11–19) NR NR
(Morschhauser et al.,
2013)
2 50 AITL n = 26 3 (1–11)m No 22m 11k 3.6 (2.8, 7.6)m 2.5m NR
PTCL-NOS n = 20 AITL: 31 AITL: 15 AITL: 3.5 AITL: 4.6
sALCL  n = 3 PTCL-NOS: 20 non-AITL:
1.9
ENKTCL n = 1
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Summary of prospective clinical trials for approved (belinostat, brentuximab vedotin, pralatrexate, and romidepsin) and investigational/off-label agents and regimens in relapsed/refractory peripheral T-cell lymphoma.
Agent/regimen and
reference
Phase N PTCL diagnoses Median
prior
therapies
(range)
Central
response
review
ORR (%) CR/CRu rate (%) Median DoR,
months
(range/95% CI)
Median
PFS,
months
Median OS,
months
Lenalidomide + vorinostat/dexamethasone
(Hopﬁnger et al., 2014) 1/2 8 AITL n = 5 NR (1–2) No 25 13 NR 2.2 6.7
PTCL-NOS n = 2
ALK− ALCL n = 1
Mogamulizumab
(Yamamoto et al.,
2010)
1 15 All CCR4+: NR (1–3+) Yes 31n 13n NR 1.5n NR
ATLL  n = 13 ATLL: 31 ATLL: 15
PTCL-NOS n = 2
(Ishida et al., 2012) 2 27 CCR4+ ATLL n = 27 NR (1–3) Yes 50 31 NR 5.2 13.7
(Ogura et al., 2014b) 2 29 CCR4+: 2 (1–5) Yes 34 17 NR 2.0 14.2
PTCL-NOS n = 16 PTCL-NOS: 19 PTCL-NOS: 6
AITL  n = 12 AITL: 50 AITL: 25
ALK−  ALCL n = 1 ALK− ALCL: 100 ALK− ALCL:
100
(Zinzani et al., 2014) 2 38 CCR4+ PTCL n = 38 2 (1–8) No 11 3 2.9o 2.1 NR
Panobinostat + bortezomib
(Goh et al., 2014) 2 25 AITL n = 8 2 (1–4) No 43 22 NR NR NR
PTCL-NOS n = 11
ALK − ALCL n = 2
ALK+ ALCL n = 1
ENKTCL n = 2
SPTCL n = 1
Plitidepsin
(Ribrag et al., 2013) 2 34 PTCL-NOS n = 17 2 (1–5) No 21 6 2.2 (0–27.9) 1.6 10.2
AITL  n = 9
ALCL n = 5
ENKTCL n = 3
AITL—angioimmunoblastic T-cell lymphoma; ALCL—anaplastic large cell lymphoma; ALK—anaplastic lymphoma kinase; Angio-TCL—angiocentric T-cell lymphoma; ATLL—adult T-cell leukemia/lymphoma; cALCL—cutaneous
anaplastic  large cell lymphoma; CR—complete response; CRu—unconﬁrmed CR; DHAP—dexamethasone, cisplatin, and cytarabine; DLBCL—diffuse large B-cell lymphoma; DoR—duration of response; EATL—enteropathy-associated
T-cell  lymphoma; ENKTCL—extranodal natural killer/T-cell lymphoma, nasal type; FCD—ﬂudarabine, cyclophosphamide, and doxorubicin; HSTCL—hepatosplenic T-cell lymphoma; MF—mycosis fungoides; NKTCL—natural killer/T-
cell  lymphoma (nasal type or extravascular); NOS—not otherwise speciﬁed; NR—not reported; ORR—overall response rate; OS—overall survival; PFS—progression-free survival; PTCL—peripheral T-cell lymphoma; sALCL—systemic
ALCL;  SPTCL—subcutaneous panniculitis-like T-cell lymphoma; SS—Sézary syndrome; TCL—T-cell lymphoma; T-ALL—T-cell acute lymphoblastic leukemia; tMF—transformed mycosis fungoides; T-PLL—T-cell prolymphocytic
leukemia.
a Time to progression.
b Brentuximab vedotin retreatment.
c Also includes patients with CTCL (diagnoses not speciﬁed).
d Data presented for 10 patients: 6 with PTCL-NOS and 4 with MF.
e Data presented for 60 patients: 58 with PTCL and 2 with MF.
f Data presented for 32 patients: 16 with PTCL (various subtypes) and 16 with DLBCL.
g Data presented for 11 patients: 9 with ALK+ ALCL and 2 with ALK + DLBCL.
h Data presented for 15 patients: 14 with ALK+ ALCL and 1 with ALK+ DLBCL.
i Data presented for 27 patients: 26 with PTCL subtypes and 1 with SS.
j Data presented for 33 patients: 16 with PTCL and 17 with CTCL.
k Data presented for 13 patients: 9 with PTCL subtypes, 2 with CTCL, and 2 with cALCL.
l Includes 8 previously untreated patients not eligible for combination chemotherapy and 2 patients with lymphoblastic TCL.
m Data presented for 54 patients: 50 with PTCL subtypes, 3 with MF,  and 1 with cALCL.
n Data presented for 16 patients: 13 with ATLL, 2 with PTCL-NOS, and 1 with MF.
o Including duration of stable disease.
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atients who have received at least one prior therapy (ISTODAX®,
015). The third approved drug is belinostat, another potent IV
class 1/2/4), epigenetic-modifying HDAC inhibitor (O’Connor et al.,
015; BELEODAQ®, 2015; Bodiford et al., 2014; Poole, 2014), which
s indicated for the treatment of patients with relapsed or refractory
TCL (BELEODAQ®, 2015). The ﬁnal approved agent is brentux-
mab vedotin, an antibody-drug conjugate (ADC) directed against
D30, a cell-surface antigen that is selectively expressed by malig-
ant cells, particularly in sALCL and variably in other TCL subtypes
Karube et al., 2008; Chen et al., 2013). Brentuximab vedotin was
ranted accelerated approval in the United States for the treatment
f sALCL after failure of at least one multiagent chemotherapy reg-
men (ADCETRIS®, 2015a), and is also approved in the European
nion for the treatment of adult patients with relapsed or refrac-
ory sALCL (ADCETRIS®, 2015b). European approvals of pralatrexate
nd romidepsin were both rejected on the grounds of lack of evi-
ence of clinical beneﬁt. Belinostat is not licensed in Europe, but has
een granted orphan designation status by the European Medicines
gency.
As would be expected from their indications, pralatrexate,
omidepsin, and belinostat were approved in the United States
ased on their activity in mixed populations of patients with PTCL
Table 1) (Foss et al., 2015; O’Connor et al., 2009, 2011, 2015; Coifﬁer
t al., 2012, 2014; Piekarz et al., 2011). Approvals were based on
esponse rates alone, as none of these agents has yet been shown
o improve OS. Importantly, all three drugs were generally well tol-
rated with no cumulative toxicity, and negligible impact on quality
f life.
Response rates reported for pralatrexate in the pivotal phase
 PROPEL trial (N = 115) were fairly consistent across different
elapsed/refractory PTCL subtypes (ORR 25–38%; combined ORR
9%, including 12 CRs), except AITL, where the ORR was much lower
8%) (Table 1) (O’Connor et al., 2011). The authors of the study sug-
ested that the lower response rates in AITL patients may  reﬂect
he unique biology of the condition or may  simply be an artifact
ue to the small sample size. Among patients who  received only
ne prior systemic treatment, the ORR was 35% (O’Connor et al.,
011), suggesting that the response rate might be higher if prala-
rexate is used early on during therapy (i.e., second line). In primary
efractory patients, the ORR was 19%, indicating the potential to
vercome resistance. Median PFS and OS were 3.5 and 14.5 months,
espectively. Although efﬁcacious, the toxicity of pralatrexate can
e signiﬁcant, especially oral mucositis (which occurred despite
upplementation with vitamin B12 and folic acid), immunosup-
ression, and thrombocytopenia (Shimanovsky and Dasanu, 2013).
s such, pralatrexate may  be unsuitable for certain patients, includ-
ng the frail and those with signiﬁcant comorbidities.
In the pivotal trial of romidepsin in relapsed/refractory PTCL
N = 130), response rates were similar among patients with PTCL-
OS (ORR 29%, CR rate 14%), AITL (ORR 30%, CR rate 19%), and
LK− ALCL (ORR 24%, CR rate 19%), but no responses were seen
n patients with rarer PTCL subtypes (Coifﬁer et al., 2012); again,
he lack of efﬁcacy in rare PTCL entities could be an anomaly
ue to the limited number of patients. A recent study update
eported that PTCL patients who responded to romidepsin could
chieve durable responses (median duration, 28 months after 22.3
onths median follow-up; range, <1–48+ months) (Coifﬁer et al.,
014). Median PFS and OS at this assessment were 4 and 11.3
onths, respectively. Like other HDAC inhibitors, side effects asso-
iated with romidepsin are predominantly hematologic in nature
nd include neutropenia, lymphopenia, thrombocytopenia, and
nemia (Khot et al., 2013a; ISTODAX®, 2015; Foss et al., 2014).
ther side effects include infections (some of which may  be seri-
us), fatigue/asthenia, nausea/vomiting, and other gastrointestinal
dverse events (AEs) (Khot et al., 2013a; ISTODAX®, 2015; Fossogy/Hematology 99 (2016) 214–227 221
et al., 2014). Electrocardiographic changes have also been reported
during romidepsin treatment, although these do not appear to be
clinically relevant for patients without pre-existing cardiac abnor-
malities (ISTODAX®, 2015; Foss et al., 2014). Belinostat treatment
resulted in response rates of a similar magnitude to those seen with
pralatrexate and romidepsin in the pivotal phase 2 BELIEF study of
129 patients with relapsed/refractory PTCL after failure of ≥1 prior
systemic therapy (ORR 26%, CR rate 11%) (O’Connor et al., 2015).
Furthermore, prolonged responses were observed in some patients
(median duration, 13.6 months; maximum duration, >36 months).
Median PFS and OS were 1.6 and 7.9 months, respectively. A sub-
group analysis suggested that belinostat may  have particularly high
activity in patients with pathologically conﬁrmed AITL (ORR 46%;
n = 22) (O’Connor et al., 2015; Horwitz et al., 2013). Because the
drug appears to have a favorable safety proﬁle, including a low risk
of grade 3/4 hematologic AEs (O’Connor et al., 2015), belinostat
may  have potential in combination regimens, and may also be suit-
able for patients with pre-existing thrombocytopenia or anemia (as
suggested in a recent subanalysis of the BELIEF data (Savage et al.,
2014).
Overall, these results suggest that pralatrexate, romidepsin, and
belinostat have similar activity to each other across a range of
PTCL subtypes; however, current data indicates that pralatrexate
should not be used to treat AITL (at least until further studies
are conducted) due to lack of efﬁcacy, belinostat may  be partic-
ularly active in AITL (an observation that requires conﬁrmation),
and romidepsin may  not be as active in patients with the rarest
PTCL subtypes. As preclinical data suggest the potential for syn-
ergy between romidepsin and pralatrexate (Jain et al., 2012), it
seems appropriate to investigate these two  agents in combination
in future studies in relapsed/refractory PTCL, and an investigator-
initiated phase 1/2 study is already underway (NCT01947140).
These agents also have the potential to act as a bridge to SCT.
The remaining approved agent, brentuximab vedotin, an ADC,
comprises an anti-CD30 chimeric antibody (cAC10) conjugated
to the microtubule-disrupting agent, monomethyl auristatin E
(MMAE) (Chen et al., 2013). Once brentuximab vedotin binds to
CD30, the ADC—receptor complex is internalized and MMAE  is
released by proteolytic cleavage. Binding of MMAE  to tubulin dis-
rupts the microtubule network within the cell, inducing cell-cycle
arrest and apoptosis. After observing a CR to brentuximab vedotin
in 2/2 patients with sALCL in a phase 1 study of 45 patients with
relapsed or refractory CD30-positive lymphomas (predominantly
Hodgkin lymphoma [HL]) (Younes et al., 2010), a dedicated, piv-
otal, phase 2 single-arm study was  conducted to evaluate the
efﬁcacy and safety of the drug in 58 patients with sALCL who had
relapsed after prior therapy (Table 1) (Pro et al., 2012). Despite
the fact the 62% of patients were primary refractory, treatment
with brentuximab vedotin was  associated with an 86% ORR by
independent review (median duration, 12.6 months), with 57% of
patients achieving a CR (median duration, 13.2 months). At the 4-
year follow-up, median PFS among all patients was 20 months and
4-year OS was 64% (Pro et al., 2014). The most frequent (≥20%)
AEs were peripheral sensory neuropathy, nausea, fatigue, pyrexia,
diarrhea, rash, constipation, and neutropenia. Results from these
phase 2 trials led to the regulatory approvals for the treatment of
relapsed/refractory sALCL, and established brentuximab vedotin as
the treatment of choice for this condition, with response rates that
are currently unsurpassed.
Following on from this trial, new data from a phase 2 study of
29 patients with HL (n = 21) or sALCL (n = 8) suggest that retreat-
ment with single-agent brentuximab vedotin (following relapse
after achieving a CR or partial response [PR] during prior bren-
tuximab vedotin therapy) can also result in high response rates in
sALCL patients (ORR 88%, CR rate 63%, median duration of response
12.3 months) similar to those seen during initial treatment (Bartlett
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t al., 2014). This illustrates the feasibility of brentuximab vedotin
etreatment in sALCL, and shows that similar high response rates
ay  be achieved on the second or third applications.
In addition to therapeutic antibodies, small molecule drugs may
lso have a role in the future treatment of relapsed/refractory PTCL.
rizotinib, for example, is a small molecule, oral tyrosine kinase
nhibitor of ALK and c-ros oncogene 1 (ROS-1) that is approved
or use in ALK+ metastatic non-small cell lung cancer (Mossé
t al., 2013; Redaelli et al., 2013; Gambacorti-Passerini et al., 2011,
013; XALKORI®, 2015). In small-scale, mixed population stud-
es, crizotinib has been shown to exert high and durable activity
n previously treated ALK+ sALCL patients (ORR 60–100%, CR rate
8–100%), while exhibiting a relatively benign safety proﬁle (Mossé
t al., 2013; Redaelli et al., 2013; Gambacorti-Passerini et al., 2011,
013). AEs associated with crizotinib, most of which are mild or
oderate, include diarrhea, nausea/vomiting, visual disturbances,
sthenia/fatigue, cough, neutropenia, and liver enzyme elevations
Mossé et al., 2013; Gambacorti-Passerini et al., 2013). Larger stud-
es are now needed to conﬁrm these initial ﬁndings.
.3. Investigational and off-label therapies in relapsed/refractory
TCL
In addition to these approved drugs, a number of novel ther-
peutic agents and regimens in various drug classes are under
nvestigation in relapsed/refractory PTCL, mainly in studies of
atients with mixed PTCL diagnoses. Some of these drugs are
lready approved for use in other hematologic malignancies
r solid tumors, while others are purely experimental. These
nvestigational agents include alisertib, bendamustine, forodesine,
anobinostat, bortezomib, denileukin diftitox, lenalidomide, alem-
uzumab, mogamulizumab, crizotinib, duvelisib, plitidepsin, and
elinexor. Available efﬁcacy data on all of these agents are summa-
ized in Table 1.
Alisertib (MLN8237) is an experimental, orally administered,
elective inhibitor of aurora A kinase (a serine-threonine protein
inase expressed on all rapidly dividing cells that regulates mitotic
pindle formation and centrosome maturation/separation during
itosis) that is being developed for the treatment of a range of
ematologic malignancies and solid tumors (Friedberg et al., 2014;
arr et al., 2015; Manfredi et al., 2011). Following demonstration
f promising single-agent activity across a range of PTCL entities
including an ORR of 30% in patients with various PTCL subtypes)
Friedberg et al., 2014; Barr et al., 2015), a randomized, open-
abel phase 3 trial has been initiated to compare the efﬁcacy and
afety of single-agent alisertib versus the investigator’s choice of
reatment (pralatrexate, gemcitabine, or romidepsin) in patients
ith relapsed/refractory PTCL (NCT01482962). The primary results
rom this trial are expected in late 2016. Phase 1 data in mixed
elapsed/refractory lymphoma subtypes also suggest the poten-
ial of combining alisertib with HDAC inhibitors (vorinostat or
omidepsin) (Siddiqi et al., 2014; Fanale et al., 2014). So far, com-
ination treatment appears tolerable (Siddiqi et al., 2014; Fanale
t al., 2014), and one of three PTCL patients treated with alis-
rtib/romidepsin has achieved a CR lasting 5+ months (Fanale et al.,
014). Common grade 3/4 alisertib-related AEs include hemato-
ogic toxicities, stomatitis/mucositis, and rash; these AEs tend to
anageable and reversible (Friedberg et al., 2014; Barr et al., 2015).
The alkylating, nitrogen mustard chemotherapeutic drug, ben-
amustine – which is used in the United States to treat chronic
ymphocytic leukemia and indolent B-cell NHL (TREANDATM, 2015)
 has been evaluated in a phase 2 trial of 60 patients with
elapsed/refractory PTCL or CTCL who had progressed after receiv-
ng one or more lines of prior chemotherapy (Damaj et al., 2013).
hile high response rates were attained across multiple PTCL sub-
ypes (including ORRs of 69% and 41% in patients with AITL andogy/Hematology 99 (2016) 214–227
PTCL-NOS, respectively), the lack of durability of response (median
duration, 3.5 months across all PTCL and CTCL subtypes) suggests
that bendamustine is more likely to be investigated in the future as
a component of combination regimens (Damaj et al., 2013). How-
ever, the short duration of response may  reﬂect the fact that nearly
half of the patients (45%) were refractory to their last treatment.
Median PFS and OS were 3.6 and 6.3 months, respectively. Grade
3/4 AEs associated with bendamustine were typical of alkylating
chemotherapies, and included hematologic toxicities, infections,
skin reactions, mucositis, and arrhythmia (Damaj et al., 2013).
Clinical data are also available for the oral purine nucleoside
phosphorylase (PNP) inhibitor, forodesine (BCX1777) (Ogura et al.,
2012). This compound is of interest as PNP is an important catalytic
enzyme in the purine salvage pathway, and its deﬁciency is associ-
ated with T-cell lymphopenia (Al-Kali et al., 2010). In a small phase
1 trial, forodesine treatment led to a durable CR (PFS 331 days)
in one patient with ALK− sALCL (Ogura et al., 2012). However, no
additional objective responses were seen in the remaining eight
patients with PTCL (six with PTCL-NOS and two with ALK− sALCL).
Treatment was generally well tolerated, apart from a high rate of
grade 3/4 lymphopenia. Although forodesine is still under active
investigation in relapsed/refractory PTCL in Japan (NCT01776411),
its clinical development appears to have been discontinued by the
manufacturer in other regions.
Given the activity of romidepsin and belinostat in
relapsed/refractory PTCL, it is unsurprising that the oral pan-
HDAC (class 1/2/4) inhibitor, panobinostat, is under evaluation in
this setting (Goh et al., 2014; Anne et al., 2013). This experimental
drug is also in clinical development in various lymphoid and
myeloid malignancies (including CTCL and multiple myeloma, for
which it has recently been approved in the United States (National
Cancer Institute, 2015b), and solid tumors (Anne et al., 2013; Khot
et al., 2013b)). In PTCL, panobinostat was assessed in combination
with the proteasome inhibitor, bortezomib, in a small phase 2
study involving 25 patients with refractory PTCL after the failure of
conventional chemotherapy (Goh et al., 2014). The ORR achieved
with this combination was  43%, including a 22% CR rate, and
treatment was  generally well tolerated (Goh et al., 2014). Drug-
related grade 3/4 AEs included thrombocytopenia, neutropenia,
diarrhea, and asthenia/fatigue. The study investigators suggest
that panobinostat/bortezomib may  serve as a bridge to allo-SCT for
eligible patients who  have failed other treatments. In this trial, ﬁve
of the 25 treated patients underwent successful transplantation
(Goh et al., 2014).
The ﬁrst-generation IV proteasome inhibitor, bortezomib, a
drug widely used in multiple myeloma and pretreated mantle cell
lymphoma (National Cancer Institute, 2015a,b), has also been com-
bined with gemcitabine in a phase 1/2 trial of patients with relapsed
or refractory PTCL or diffuse large B-cell lymphoma (DLBCL) (Evens
et al., 2013). An ORR of 36% (CR rate 27%) was observed in 16 PTCL
patients treated with bortezomib/gemcitabine (Evens et al., 2013).
Among six PTCL patients who received a schedule that was  modi-
ﬁed to improve hematologic tolerability, the ORR was an impressive
50%. Though patient numbers were small, the modiﬁed schedule
appeared to be reasonably well tolerated with a low incidence of
grade 3/4 hematologic AEs.
The interleukin-2 (IL-2)–diphtheria toxin fusion protein,
denileukin diftitox is an approved treatment for patients with per-
sistent or recurrent CTCL whose cells express the CD25 component
of the IL-2 receptor (ONTAK®, 2014). In a small phase 2 trial of 27
patients with relapsed/refractory PTCL, denileukin diftitox treat-
ment was associated with high response rates (ORR 48%, CR rate
22%), particularly among patients with CD25+ lymphomas (ORR
62%) (Dang et al., 2007). This led to further development of this
unique agent in the frontline setting, where impressive results have
been shown for denileukin diftitox when combined with CHOP
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Foss et al., 2013). However, supply of denileukin diftitox for general
se has been on hold since 2011 (with product discontinuation in
014) due to the risk of serious toxicities (capillary leak syndrome,
nfusion reactions, and visual loss (ONTAK®, 2014)). While further
evelopment of denileukin diftitox per se is unlikely to be pursued
n PTCL, clinical trials of an improved purity formulation (E7777)
re ongoing in previously treated CTCL (Duvic et al., 2014) and
TCL (NCT01401530). It is too early to say whether this improved
ormulation will result in a better tolerability proﬁle.
Another toxic compound, plitidepsin – an investigational cyto-
oxic cyclodepsipeptide originally isolated from the Mediterranean
unicate Aplidium albicans – has demonstrated signs of anti-
ymphoma activity (ORR 21%, including two CRs) in 29 patients
ith non-cutaneous PTCL participating in a phase 2 trial in mixed
elapsed/refractory, aggressive NHL (Ribrag et al., 2013). It is not
nown, however, whether development of plitidepsin in PTCL will
e pursued, as no clinical trials are ongoing or planned for this
ndication.
The orally administered, immunomodulatory, synthetic thalido-
ide derivative, lenalidomide, which is widely used to treat
ultiple myeloma and mantle cell lymphoma (REVLIMID®, 2015),
as been investigated in several studies in relapsed/refractory PTCL
Dueck et al., 2010; Toumishey et al., 2015; Zinzani et al., 2011;
orschhauser et al., 2013). As monotherapy, this drug has achieved
esponses in heavily pretreated PTCL patients (ORR 22–30%, CR rate
–30%), particularly those with AITL, sALCL, or PTCL-NOS, and has
 predictable AE proﬁle (common grade 3/4 AEs included hema-
ologic, gastrointestinal, and constitutional toxicities) (Toumishey
t al., 2015; Zinzani et al., 2011; Morschhauser et al., 2013). These
esponse rates and other efﬁcacy measures, including PFS and OS,
re very similar to those reported for single-agent romidepsin,
elinostat, and pralatrexate in relapsed/refractory PTCL (Table 1).
owever, the beneﬁts of lenalidomide must be weighed up against
he potential risks of serious AEs, such as embryo-fetal toxic-
ty, thromboembolism, allergic reactions, tumor lysis syndrome,
nd tumor ﬂare reaction, as observed in other malignancies
REVLIMID®, 2015). As well as in monotherapy, lenalidomide may
lso form a component of combination regimens. Disappointingly,
 small phase 1/2 study of 8 patients with relapsed/refractory
TCL reported no additional beneﬁt (ORR 25%, median PFS 2.2
onths, median OS 6.7 months), compared with published reports
or monotherapy, when lenalidomide was combined with vorinos-
at (an oral HDAC inhibitor approved for use in relapsed/refractory
TCL (ZOLINZA®, 2015) and dexamethasone (Hopﬁnger et al.,
014). This ﬁnding was, however, attributed to the poor tolerabil-
ty of the regimen, which restricted the dose of lenalidomide to a
aximum of 5 mg/day. The approved dose of lenalidomide in other
ematologic malignancies is 25 mg/day (REVLIMID®, 2015).
It is likely that future regimens in relapsed/refractory PTCL will
eature target-speciﬁc monoclonal antibodies that act, amongst
ther ways, to promote antibody-dependent cellular toxicity and
poptosis in malignant T-cells (Ogura et al., 2014a; Zinzani et al.,
012). In this regard, the humanized, anti-CD52 monoclonal
ntibody, alemtuzumab, has been evaluated clinically both as
onotherapy and in combination with chemotherapy (FCD, DHAP,
r pentostatin) (Enblad et al., 2004; Zinzani et al., 2005; Ravandi
t al., 2009; Weidmann et al., 2010; Kim et al., 2009). This antibody
argets the CD52 cell-surface glycoprotein antigen of unknown
unction expressed on T cells, B cells, and some other immune cells
Zinzani et al., 2012). Despite showing encouraging single-agent
nd combined activity in relapsed/refractory PTCL (ORR 36–55%)
Enblad et al., 2004; Zinzani et al., 2005; Ravandi et al., 2009;
eidmann et al., 2010; Kim et al., 2009), recent research on alem-
uzumab has predominantly focused on ﬁrst-line treatment, where
t is has been combined with CHOP, ESHAP, and dose-adjusted
POCH (Zinzani et al., 2012). It should be noted that while alem-ogy/Hematology 99 (2016) 214–227 223
tuzumab is approved to treat B-cell chronic lymphocytic leukemia,
it is no longer available commercially in the United States, and can
only be obtained via a distribution program. This is because the
therapeutic antibody is linked with an increased risk of serious and
sometimes fatal cytopenias, infusion reactions, and opportunis-
tic infections (Campath®, 2015). It is also no longer authorized in
Europe.
Another therapeutic antibody under investigation in
relapsed/refractory PTCL is the defucosylated, humanized, mon-
oclonal antibody, mogamulizumab (KY-0761), that targets CC
chemokine receptor 4 (CCR4), a marker for type 2 helper T cells
or regulatory T (Treg) cells that is variably expressed in most
PTCLs, but widely expressed in ATLL (Yamamoto et al., 2010; Ishida
et al., 2012; Ogura et al., 2014b). Mogamulizumab demonstrated
particularly high activity in Japanese patients with previously
treated, relapsed CCR4+ ATLL (ORR 50%, CR rate 31%, median PFS
5.2 months, median OS 13.7 months) without many of the serious
autoimmune side effects associated with alemtuzumab (Ishida
et al., 2012). Based on these data, mogamulizumab was  approved
for the treatment of relapsed or refractory ATLL in Japan in 2012
(Subramaniam et al., 2012). This indication was subsequently
extended in 2014 to include previously treated patients with PTCL
or CTCL based on the results of a phase 2 Japanese trial, which
reported an ORR of 35% (34% in PTCL) and CR rate of 14% in patients
who had relapsed after their last systemic therapy (Ogura et al.,
2014b). For European and United States regulatory purposes, a
randomized controlled phase 3 trial is currently investigating
the efﬁcacy and safety of mogamulizumab versus investigator’s
choice of treatment (pralatrexate; gemcitabine plus oxaliplatin;
or dexamethasone, cisplatin, and cytarabine) in patients with
previously treated ATLL, excluding smoldering type, who  have
relapsed or are refractory after at least 1 prior systemic therapy
(Phillips et al., 2014). Interestingly, a recent phase 2 trial of
mogamulizumab in 38 European patients with relapsed/refractory
CCR4+ PTCL only reported an ORR of 11% (Zinzani et al., 2014),
which is much lower than that reported in Japanese patients
(Ogura et al., 2014b). The study investigators attributed the low
response rate to the inclusion of a high proportion of refractory
patients (49%), and differences in performance status and response
assessment. Median PFS was, nevertheless, similar in the two
trials. Mogamulizumab-related AEs, which are mainly low grade,
include infusion reactions, hematologic toxicities, fever, chills,
nausea, skin disorders, and liver transaminase elevations (Ishida
et al., 2012; Ogura et al., 2014b; Zinzani et al., 2014).
In addition to therapeutic antibodies, small molecule drugs may
also have a role in the future treatment of relapsed/refractory
PTCL. Crizotinib, for example, is a small molecule, oral tyrosine
kinase inhibitor of ALK and c-ros oncogene 1 (ROS-1) that is
approved for use in ALK+ metastatic non-small cell lung cancer
(Mossé et al., 2013; Redaelli et al., 2013; Gambacorti-Passerini
et al., 2011,2013; XALKORI®, 2015). In small-scale, mixed popu-
lation studies, crizotinib has been shown to exert high and durable
activity in previously treated ALK+ sALCL patients (ORR 60–100%,
CR rate 38–100%), while exhibiting a relatively benign safety pro-
ﬁle (Mossé et al., 2013; Redaelli et al., 2013; Gambacorti-Passerini
et al., 2011, 2013). AEs associated with crizotinib, most of which are
mild or moderate, include diarrhea, nausea/vomiting, visual dis-
turbances, asthenia/fatigue, cough, neutropenia, and liver enzyme
elevations (Mossé et al., 2013; Gambacorti-Passerini et al., 2013).
Larger studies are now needed to conﬁrm these initial ﬁndings.
Another small molecule oral drug, duvelisib (IPI-145), which
inhibits phosphoinositide-3-kinases  and  (important enzymes
preferentially expressed by leukocytes, which are involved in reg-
ulating malignant T-cell growth and survival (Horwitz et al., 2014b;
Winkler et al., 2013), may  have utility in previously treated PTCL
(Horwitz et al., 2014b). Data from a disease-speciﬁc cohort of
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atients with relapsed/refractory PTCL or CTCL participating in
n ongoing phase 1 study showed that duvelisib treatment could
chieve an ORR of 47% (including two CRs) in 15 evaluable PTCL
atients (Horwitz et al., 2014b). Median OS in PTCL patients was
6.4 weeks and the most common grade 3/4 AEs among all patients
ere elevated liver transaminases, rash, and neutropenia. Based on
hese data, duvelisib appears to be highly active in PTCL and further
tudy is justiﬁed.
Finally, the oral selective inhibitor of nuclear export (SINE),
elinexor (KPT-330), may  be active in relapsed/refractory PTCL
Kuruvilla et al., 2014). This XPO1 (Exportin-1/Chromosome Region
aintenance 1/CRM1) antagonist acts to block nucleo-cytoplasmic
ransport of nuclear proteins in malignant cells, thereby facilitat-
ng apoptosis (Kuruvilla et al., 2014; Gravina et al., 2014). Based on
arly signs of activity in TCL (CR in 1/5 patients) in a phase 1 trial
f a mixed population of 58 patients with relapsed/refractory NHL
Kuruvilla et al., 2014), a multicenter phase 2 trial in relapsed or
efractory PTCL or CTCL patients is planned (NCT02314247). Treat-
ent with selinexor appears to be generally well tolerated when
upportive care measures are instigated; toxicities include hema-
ologic AEs, fatigue, nausea/vomiting, and anorexia (Kuruvilla et al.,
014).
. Concluding remarks
This paper has aimed to thoroughly review the current and
uture pharmacologic options for relapsed and/or refractory PTCLs.
onventional chemotherapy remained the only option for pre-
reated PTCL for many years, but over the past decade we have
itnessed a transformation in the way these refractory malig-
ancies are managed. Hematopoietic transplantation appears to
e an effective treatment approach in relapsed/refractory PTCL
Perrone et al., 2013; Perrone and Corradini, 2014; Schmitz et al.,
014; Gkotzamanidou and Papadimitriou, 2014). However, not all
atients are ‘ﬁt’ enough to undergo these procedures and, as with
ll treatment strategies, not all patients achieve successful post-
ransplant outcomes. With an increasing armory of drugs, we  will
oon be able to target particular PTCL subtypes, as has been done
ith great success with brentuximab vedotin in relapsed/refractory
ALCL, and move toward individualized therapy. Over the next few
ears, we are likely to see further drug treatment options become
vailable as larger phase 2 studies and phase 3 trials (e.g., alis-
rtib in PTCL and mogamulizumab in ATLL), which to date have
een scarce in this setting, bear results. Trials of combinations of
ovel agents and standard chemotherapies are also expected in the
uture, for it is likely that combined treatment approaches will yield
he most favorable outcomes, as has been seen in other oncology
nd hematology settings. Novel therapies may  also be used earlier
n in the disease process. For example, phase 3 trials of brentux-
mab vedotin (combined with CHP vs CHOP in mature CD30+ TCL;
CT01777152), romidepsin (combined with CHOP vs CHOP alone in
TCL; NCT01796002), and alemtuzumab (combined with CHOP14
s CHOP14 alone in PTCL, except sALCL; NCT00646854 [accrual now
losed]) are progressing in the frontline setting in newly diagnosed
atients. Until a cure becomes available, the goal of treatment in
elapsed/refractory PTCL, as in the frontline setting, will remain
s the prevention of disease progression and maintenance of an
ptimal quality of life.
onﬂict of interestEmployment: V.B. (Takeda), D.H. (Takeda), R.L. (Takeda), A.C.
Takeda).
Stock ownership: A.C. (Takeda).ogy/Hematology 99 (2016) 214–227
Conﬂicts of interest: P.L.Z., S.P. advisory board membership
(Takeda).
Funding
The development of this publication was funded by Millen-
nium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda
Pharmaceutical Company Ltd. Vijayveer Bonthapally, Dirk Hueb-
ner, Richard Lutes, and Andy Chi are employed by Millennium.
Acknowledgments
The authors would like to acknowledge the writing assistance
of Duncan Campbell of FireKite, an Ashﬁeld Company, part of UDG
Healthcare plc, during the development of this publication, which
was funded by Millennium Pharmaceuticals Inc., a wholly owned
subsidiary of Takeda Pharmaceutical Company Ltd, and complied
with Good Publication Practice 3 ethical guidelines (Battisti WP,
et al. Ann Intern Med  2015;163:461–4.) All authors were involved
in drafting the article or revising it critically for important intellec-
tual content, and have approved the ﬁnal draft for submission.
References
ADCETRIS® (brentuximab vedotin) for injection, 2015a. Full Prescribing
Information. Seattle Genetics, Inc., Bothell, WA,  USA (accessed 05.02.15.).
http://www.adcetris.com/pdf/ADCETRIS-brentuximab-vedotin-Prescribing-
Information.pdf.
ADCETRIS® 50 mg powder for concentrate for solution for infusion, 2015b.
Summary of Product Characteristics. Takeda Pharma A/S, Roskilde, Denmark
(accessed 05.02.15.). http://www.ema.europa.eu/docs/en GB/document
library/EPAR - Product Information/human/002455/WC500135055.pdf.
Advani, R., Horwitz, S., Zelenetz, A., Horning, S.J., 2007. Angioimmunoblastic T cell
lymphoma: treatment experience with cyclosporine. Leuk. Lymphoma 48 (3),
521–525, http://dx.doi.org/10.1080/10428190601137658.
Ahn, H.K., Kim, S.J., Hwang, D.W., et al., 2013. Gemcitabine alone and/or containing
chemotherapy is efﬁcient in refractory or relapsed NK/T-cell lymphoma. Invest.
New Drugs 31 (2), 469–472, http://dx.doi.org/10.1007/s10637-012-9889-4.
Al-Kali, A., Gandhi, V., Ayoubi, M.,  et al., 2010. Forodesine: review of preclinical and
clinical data. Future Oncol. 6 (8), 1211–1217, http://dx.doi.org/10.2217/fon.10.
83.
Anne, M., Sammartino, D., Barginear, M.F., et al., 2013. Proﬁle of panobinostat and
its  potential for treatment in solid tumors: an update. Onco Targets Ther. 6,
1613–1624, http://dx.doi.org/10.2147/ott.s30773.
Arkenau, H.T., Chong, G., Cunningham, D., et al., 2007. Gemcitabine, cisplatin and
methylprednisolone for the treatment of patients with peripheral T-cell
lymphoma: the royal marsden hospital experience. Haematologica 92 (2),
271–272, http://dx.doi.org/10.3324/haematol.10737.
BELEODAQ® (belinostat) for injection, for intravenous administration, 2015. Full
prescribing information. Revised: 7/2014. Spectrum Pharmaceuticals, Inc.,
Irvine, CA, USA (accessed 05.02.15.). http://www.accessdata.fda.gov/
drugsatfda docs/label/2014/206256lbl.pdf.
Barr, P.M., Li, H., Spier, C., et al., 2015. Phase II Intergroup trial of alisertib in
relapsed and refractory peripheral T-cell lymphoma and transformed mycosis
fungoides: SWOG 1108. J. Clin. Oncol. 33 (21), 2399–2404, http://dx.doi.org/10.
1200/JCO. 2014.60.6327.
Bartlett, N.L., Chen, R., Fanale, M.A., et al., 2014. Retreatment with brentuximab
vedotin in patients with CD30-positive hematologic malignancies. J. Hematol.
Oncol. 7, 24, http://dx.doi.org/10.1186/1756-8722-7-24.
Bodiford, A., Bodge, M.,  Talbott, M.S., et al., 2014. Proﬁle of belinostat for the
treatment of relapsed or refractory peripheral T-cell lymphoma. Onco Targets
Ther. 7, 1971–1977, http://dx.doi.org/10.2147/ott.s59269.
Campath® (alemtuzumab), 2015. Injection for intravenous use. Full prescribing
information. Revised: 9/. Genzyme Corporation, Cambridge, MA,  USA (accessed
05.02.15.). http://www.campath.com/pdfs/2014-09-Campath US PI.pdf.
Chen, X., Soma, L.A., Fromm, J.R., 2013. Targeted therapy for Hodgkin lymphoma
and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin.
Onco Targets Ther. 7, 45–56, http://dx.doi.org/10.2147/ott.s39107.
Chihara, D., Ito, H., Katanoda, K., et al., 2012. Increase in incidence of adult T-cell
leukemia/lymphoma in non-endemic areas of Japan and the United States.
Cancer Sci. 103 (10), 1857–1860, http://dx.doi.org/10.1111/j.1349-7006.2012.
02373.x.
Coifﬁer, B., Pro, B., Prince, H.M., et al., 2012. Results from a pivotal, open-label,
phase II study of romidepsin in relapsed or refractory peripheral T-cell
lymphoma after prior systemic therapy. J. Clin. Oncol. 30 (6), 631–636, http://
dx.doi.org/10.1200/JCO.2011.37.4223.
Coifﬁer, B., Pro, B., Prince, H.M., et al., 2014. Romidepsin for the treatment of
relapsed/refractory peripheral T-cell lymphoma: pivotal study update
 Oncol
D
D
D
D
D
D
D
D
E
E
E
F
F
F
F
F
F
F
G
G
G
G
G
GP.L. Zinzani et al. / Critical Reviews in
demonstrates durable responses. J. Hematol. Oncol. 7 (1), 11, http://dx.doi.org/
10.1186/1756-8722-7-11.
amaj, G., Gressin, R., Bouabdallah, K., et al., 2013. Results from a prospective,
open-label, phase II trial of bendamustine in refractory or relapsed T-cell
lymphomas: the BENTLY trial. J. Clin. Oncol. 31 (1), 104–110, http://dx.doi.org/
10.1200/JCO.2012.43.7285.
ang, N.H., Pro, B., Hagemeister, F.B., et al., 2007. Phase II trial of denileukin diftitox
for relapsed/refractory T-cell non-Hodgkin lymphoma. Br. J. Haematol. 136 (3),
439–447, http://dx.doi.org/10.1111/j.1365-2141.2006.06457.x.
earden C., Johnson R., Pettengell R., et al., 2015. British Committee for Standards
in Haematology (BCSH) guidelines for the management of mature T-cell and
NK-cell neoplasms (excluding cutaneous T-cell lymphoma). Updated August
2013. Available at: http://www.bcshguidelines.com. (accessed 06.02.15.).
incol, D., Buyukcelik, A., Dogan, M.,  et al., 2010. Long-term outcome of mesna,
ifosfamide, mitoxantrone, etoposide (MINE) regimen as a consolidation in
patients with aggressive non-Hodgkin lymphoma responding to CHOP. Med.
Oncol. 27 (3), 942–945, http://dx.doi.org/10.1007/s12032-009-9313-x.
ong, M.,  He, X.H., Liu, P., et al., 2013. Gemcitabine-based combination regimen in
patients with peripheral T-cell lymphoma. Med. Oncol. 30 (1), 351, http://dx.
doi.org/10.1007/s12032-012-0351-4.
reyling, M.,  Thieblemont, C., Gallamini, A., et al., 2013. ESMO Consensus
conferences: guidelines on malignant lymphoma. part 2: marginal zone
lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann. Oncol.
24  (4), 857–877, http://dx.doi.org/10.1093/annonc/mds643.
ueck, G., Chua, N., Prasad, A., et al., 2010. Interim report of a phase 2 clinical trial
of lenalidomide for T-cell non-Hodgkin lymphoma. Cancer 116 (19),
4541–4548, http://dx.doi.org/10.1002/cncr.25377.
uvic, M.,  Kuzel, T.M., Dang, N.H., et al., 2014. A dose ﬁnding lead-in study of
E7777 (diphtheria toxin fragment-interleukin-2 fusion protein) in persistent
or recurrent cutaneous T-cell lymphoma (CTCL). Blood 124 (21), abstract 3097.
mmanouilides, C., Colovos, C., Pinter-Brown, L., et al., 2004. Pilot study of
ﬁxed-infusion rate gemcitabine with cisplatin and dexamethasone in patients
with relapsed or refractory lymphoma. Clin. Lymphoma 5 (1), 45–49, http://dx.
doi.org/10.3816/CLM.2004.n.009.
nblad, G., Hagberg, H., Erlanson, M.,  et al., 2004. A pilot study of alemtuzumab
(anti-CD52 monoclonal antibody) therapy for patients with relapsed or
chemotherapy-refractory peripheral T-cell lymphomas. Blood 103 (8),
2920–2924, http://dx.doi.org/10.1182/blood-2003-10-3389.
vens, A.M., Rosen, S.T., Helenowski, I., et al., 2013. A phase I/II trial of bortezomib
combined concurrently with gemcitabine for relapsed or refractory DLBCL and
peripheral T-cell lymphomas. Br. J. Haematol. 163 (1), 55–61, http://dx.doi.org/
10.1111/bjh.12488.
OLOTYN® (pralatrexate injection), 2012. Solution for intravenous injection. Full
prescribing information. Revised: 5/2012. Allos Therapeutics, Inc.,
Westminster, CO, USA (accessed 06.02.15.). http://www.folotyn.com/sites/
default/ﬁles/pdf/folotyn.pdf.
anale, M.A., Hagemeister, F.B., Fayad, L., et al., 2014. A Phase I trial of alisertib plus
romidepsin for relapsed/refractory aggressive B- and T-Cell lymphomas. Blood
124  (21), abstract 1744.
oss, F.M., Zinzani, P.L., Vose, J.M., et al., 2011. Peripheral T-cell lymphoma. Blood
117 (25), 6756–6767, http://dx.doi.org/10.1182/blood-2010-05-231548.
oss, F.M., Sjak-Shie, N., Goy, A., et al., 2013. A multicenter phase II trial to
determine the safety and efﬁcacy of combination therapy with denileukin
diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in
untreated peripheral T-cell lymphoma: the CONCEPT study. Leuk. Lymphoma
54 (7), 1373–1379, http://dx.doi.org/10.3109/10428194.2012.742521.
oss, F., Coifﬁer, B., Horwitz, S., et al., 2014. Tolerability to romidepsin in patients
with relapsed/refractory T-cell lymphoma. Biomarkers Res. 2, 16, http://dx.doi.
org/10.1186/2050-7771-2-16.
oss, F., Advani, R., Duvic, M.,  et al., 2015. A Phase II trial of belinostat (PXD101) in
patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.
Br. J. Haematol. 168 (6), 811–819, http://dx.doi.org/10.1111/bjh.13222.
riedberg, J.W., Mahadevan, D., Cebula, E., et al., 2014. Phase II study of alisertib, a
selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B-
and T-cell non-Hodgkin lymphomas. J. Clin. Oncol. 32 (1), 44–50, http://dx.doi.
org/10.1200/JCO.2012.46.8793.
ambacorti-Passerini, C., Messa, C., Pogliani, E.M., 2011. Crizotinib in anaplastic
large-cell lymphoma. N. Engl. J. Med. 364 (8), 775–776, http://dx.doi.org/10.
1056/nejmc1013224.
ambacorti-Passerini, C., Horibe, K., Braiteh, F., et al., 2013. Safety and clinical
activity of crizotinib in patients with ALK-rearranged hematologic
malignancies. Blood 122 (21), abstract 4342.
kotzamanidou, M.,  Papadimitriou, C.A., 2014. Peripheral T-cell lymphoma: the
role  of hematopoietic stem cell transplantation. Crit. Rev. Oncol. Hematol. 89
(2),  248–261, http://dx.doi.org/10.1016/j.critrevonc.2013.08.016.
oh, Y.-T., Hwang, W.Y.K., Diong, C.P., et al., 2014. A Phase 2 Study of panobinostat
(PAN) in combination with bortezomib (BTZ) in patients with
relapsed/refractory peripheral T-cell lymphoma (PTCL) or NK/T-cell lymphoma
(NKL). Blood 124 (21), abstract 503.
ravina, G., Senapedis, W.,  McCauley, D., et al., 2014. Nucleo-cytoplasmic transport
as a therapeutic target of cancer. J. Hematol. Oncol. 7, 85, http://dx.doi.org/10.
1186/s13045-014-0085-1.
uenova, E., Hoetzenecker, W.,  Rozati, S., et al., 2014. Novel therapies for
cutaneous T-cell lymphoma: what does the future hold? Expert Opin. Investig.
Drugs 23 (4), 457–467, http://dx.doi.org/10.1517/13543784.2014.876407.ogy/Hematology 99 (2016) 214–227 225
Hopﬁnger, G., Nösslinger, T., Lang, A., et al., 2014. Lenalidomide in combination
with vorinostat and dexamethasone for the treatment of relapsed/refractory
peripheral T cell lymphoma (PTCL): report of a phase I/II trial. Ann. Hematol.
93  (3), 459–462, http://dx.doi.org/10.1007/s00277-014-2009-0.
Horwitz, S., O’Connor, O., Jurczak, W.,  et al., 2013. Belinostat in relapsed or
refractory peripheral T-cell lymphoma (R/R PTCL) subtype angioimmunoblastic
T-cell lymphoma (AITL): results from the pivotal BELIEF trial. Hematol. Oncol.
31  (Suppl. 1), 147–148, http://dx.doi.org/10.1002/hon.2057 (abstract 153).
Horwitz, S.M., Advani, R.H., Bartlett, N.L., et al., 2014a. Objective responses in
relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood 123
(20), 3095–3100, http://dx.doi.org/10.1182/blood-2013-12-542142.
Horwitz, S.M., Porcu, P., Flinn, I., et al., 2014b. Duvelisib (IPI-145), a
phosphoinositide-3-kinase-, inhibitor, shows activity in patients with
relapsed/refractory T-cell lymphoma. Blood 124 (21), abstract 803.
ISTODAX® (romidepsin) for injection, 2015. Full prescribing information. Revised:
10/2014. Celgene Corporation, Summit, NJ, USA (accessed 05.02.15.). http://
www.istodax.com/pdfs/ISTODAX PackageInsert 11192009.pdf.
Ishida, T., Joh, T., Uike, N., et al., 2012. Defucosylated anti-CCR4 monoclonal
antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a
multicenter phase II study. J. Clin. Oncol. 30 (8), 837–842, http://dx.doi.org/10.
1200/JCO.2011.37.3472.
Jaccard, A., Gachard, N., Marin, B., GELA and GOELAMS Intergroup, et al., 2011.
Efﬁcacy of L-asparaginase with methotrexate and dexamethasone
(AspaMetDex regimen) in patients with refractory or relapsing extranodal
NK/T-cell lymphoma, a phase 2 study. Blood 117 (6), 1834–1839, http://dx.doi.
org/10.1182/blood-2010-09-307454.
Jain, S., Jirau-Serrano, X., Palermo, F.C., et al., 2012. Novel imaging modalities in
innovative xenograft mouse model of T-cell lymphoma conﬁrm marked
synergy of romidepsin and pralatrexate. Blood 120 (21), abstract 2758.
Karlin, L., Coifﬁer, B., 2014. The changing landscape of peripheral T-cell lymphoma
in  the era of novel therapies. Semin. Hematol. 51 (1), 25–34, http://dx.doi.org/
10.1053/j.seminhematol.2013.11.001.
Karube, K., Aoki, R., Nomura, Y., et al., 2008. Usefulness of ﬂow cytometry for
differential diagnosis of precursor and peripheral T-cell and NK-cell
lymphomas: analysis of 490 cases. Pathol. Int. 58 (2), 89–97, http://dx.doi.org/
10.1111/j.1440-1827.2007.02195.x.
Khot, A., Dickinson, M.,  Prince, H.M., 2013a. Romidepsin for peripheral T-cell
lymphoma. Expert Rev. Hematol. 6 (4), 351–359, http://dx.doi.org/10.1586/
17474086.2013.814833.
Khot, A., Dickinson, M.,  Prince, H.M., 2013b. Panobinostat in lymphoid and myeloid
malignancies. Expert Opin. Investig. Drugs 22 (9), 1211–1223, http://dx.doi.
org/10.1517/13543784.2013.815165.
Kim, S.J., Kim, K., Kim, B.S., et al., 2009. Alemtuzumab and DHAP (A-DHAP) is
effective for relapsed peripheral T-cell lymphoma, unspeciﬁed: interim results
of  a phase II prospective study. Ann. Oncol. 20 (2), 390–392, http://dx.doi.org/
10.1093/annonc/mdn726.
Kuruvilla, J., Byrd, J.C., Flynn, J.M., et al., 2014. The oral selective inhibitor of nuclear
export (SINE) selinexor (KPT-330) demonstrates broad and durable clinical
activity in relapsed/refractory non Hodgkin’s lymphoma (NHL). Blood 124 (21),
abstract 396.
Kwong, Y.L., Kim, W.S., Lim, S.T., et al., 2012. SMILE for natural killer/T-cell
lymphoma: analysis of safety and efﬁcacy from the Asia Lymphoma Study
Group. Blood 120 (15), 2973–2980, http://dx.doi.org/10.1182/blood-2012-05-
431460.
López, A., Gutiérrez, A., Palacios, A., et al., 2008. GEMOX-R regimen is a highly
effective salvage regimen in patients with refractory/relapsing diffuse
large-cell lymphoma: a phase II study. Eur. J. Haematol. 80 (2), 127–132, http://
dx.doi.org/10.1111/j.1600-0609.2007.00996.x.
Lunning, M.A., Horwitz, S., 2013. Treatment of peripheral T-cell lymphoma: are we
data driven or driving the data? Curr. Treat. Options Oncol. 14 (2), 212–223,
http://dx.doi.org/10.1007/s11864-013-0232-x.
Mak, V., Hamm,  J., Chhanabhai, M.,  et al., 2013. Survival of patients with peripheral
T-cell lymphoma after ﬁrst relapse or progression: spectrum of disease and
rare long-term survivors. J. Clin. Oncol. 31 (16), 1970–1976, http://dx.doi.org/
10.1200/JCO. 2012.44.7524.
Malik, S.M., Liu, K., Qiang, X., et al., 2010. Folotyn (pralatrexate injection) for the
treatment of patients with relapsed or refractory peripheral T-cell lymphoma:
U.S.  Food and Drug Administration drug approval summary. Clin. Cancer Res.
16  (20), 4921–4927, http://dx.doi.org/10.1158/1078-0432.ccr-10-1214.
Manfredi, M.G., Ecsedy, J.A., Chakravarty, A., et al., 2011. Characterization of
alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A
kinase using novel in vivo pharmacodynamic assays. Clin. Cancer Res. 17 (24),
7614–7624, http://dx.doi.org/10.1158/1078-0432.ccr-11-1536.
Mayer, J., Korístek, Z., Vásová, I., et al., 1999. Ifosfamide and etoposide-based
chemotherapy as salvage and mobilizing regimens for poor prognosis
lymphoma. Bone Marrow Transplant. 23 (5), 413–419.
Mey, U.J., Orlopp, K.S., Flieger, D., et al., 2006. Dexamethasone, high-dose
cytarabine, and cisplatin in combination with rituximab as salvage treatment
for patients with relapsed or refractory aggressive non-Hodgkin’s lymphoma.
Cancer Invest. 24 (6), 593–600, http://dx.doi.org/10.1080/
07357900600814490.Morschhauser, F., Fitoussi, O., Haioun, C., et al., 2013. A phase 2, multicentre,
single-arm, open-label study to evaluate the safety and efﬁcacy of single-agent
lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral
T-cell non-Hodgkin lymphoma: the EXPECT trial. Eur. J. Cancer 49 (13),
2869–2876, http://dx.doi.org/10.1016/j.ejca.2013.04.029.
2  Oncol
M
M
N
N
N
O
O
O
O
O
O
O
P
P
P
P
P
P
P
P
P
R26 P.L. Zinzani et al. / Critical Reviews in
orton, L.M., Wang, S.S., Devesa, S.S., et al., 2006. Lymphoma incidence patterns by
WHO  subtype in the United States, 1992–2001. Blood 107 (1), 265–276, http://
dx.doi.org/10.1182/blood-2005-06-2508.
ossé, Y.P., Lim, M.S., Voss, S.D., et al., 2013. Safety and activity of crizotinib for
paediatric patients with refractory solid tumours or anaplastic large-cell
lymphoma: a Children’s Oncology Group phase 1 consortium study. Lancet.
Oncol. 14 (6), 472–480, http://dx.doi.org/10.1016/s1470-2045(13)70095-0.
ational Cancer Institute, 2015. NCCN Clinical Practice Guidelines in Oncology
(NCCN Guidelines®). Non-Hodgkin’s Lymphomas. Version 2.2015. Available at:
http://www.nccn.org/professionals/physician gls/f guidelines.asp#site.
(accessed 10.11.15.).
ational Cancer Institute, 2015. NCCN Clinical Practice Guidelines in Oncology
(NCCN Guidelines®). Multiple Myeloma. Version 2.2016. Available at: http://
www.nccn.org/professionals/physician gls/f guidelines.asp#sire. (accessed
10.11.15.).
g, M., Waters, J., Cunningham, D., et al., 2005. Gemcitabine, cisplatin and
methylprednisolone (GEM-P) is an effective salvage regimen in patients with
relapsed and refractory lymphoma. Br. J. Cancer 92 (8), 1352–1357, http://dx.
doi.org/10.1038/sj.bjc.6602514.
’Connor, O.A., Horwitz, S., Hamlin, P., et al., 2009. Phase II-I-II study of two
different doses and schedules of pralatrexate, a high-afﬁnity substrate for the
reduced folate carrier, in patients with relapsed or refractory lymphoma
reveals marked activity in T-cell malignancies. J. Clin. Oncol. 27 (26),
4357–4364, http://dx.doi.org/10.1200/JCO.2008.20.8470.
’Connor, O.A., Pro, B., Pinter-Brown, L., et al., 2011. Pralatrexate in patients with
relapsed or refractory peripheral T-cell lymphoma: results from the pivotal
PROPEL study. J. Clin. Oncol. 29 (9), 1182–1189, http://dx.doi.org/10.1200/JCO.
2010.29.9024.
’Connor, O.A., Horwitz, S., Masszi, T., et al., 2015. Belinostat in patients with
relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase
II  BELIEF (CLN-19) study. J. Clin. Oncol. 33 (23), 2492–2499, http://dx.doi.org/
10.1200/JCO.2014.59.2782.
NTAK® (denileukin diftitox) injection for intravenous infusion, 2014. Full
prescribing information. Revised: August 2011. Eisai Inc., Woodcliffe Lake, NJ,
USA (accessed 17.07.14.). http://us.eisai.com/wps/wcm/connect/eisai/Home/
resources/ffc697804fdfb662a249a2c7586bf6dd/OntakPI.pdf.
gura, M., Tsukasaki, K., Nagai, H., et al., 2012. Phase I study of BCX1777
(forodesine) in patients with relapsed or refractory peripheral T/natural
killer-cell malignanciese. Cancer Sci. 103 (7), 1290–1295, http://dx.doi.org/10.
1111/j.1349-7006.2012.02287.x.
gura, M., Tobinai, K., Hatake, K., et al., 2014a. Phase I/II study of brentuximab
vedotin in Japanese patients with relapsed or refractory CD30-positive
Hodgkin’s lymphoma or systemic anaplastic large-cell lymphoma. Cancer Sci.
105 (7), 840–846, http://dx.doi.org/10.1111/cas.12435.
gura, M., Ishida, T., Hatake, K., et al., 2014b. Multicenter phase II study of
mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4
antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous
T-cell lymphoma. J. Clin. Oncol. 32 (11), 1157–1163, http://dx.doi.org/10.1200/
JCO.2013.52.0924.
ark, B.B., Kim, W.S., Suh, C., et al., 2015. Salvage chemotherapy of gemcitabine,
dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory
peripheral T-cell lymphomas: a consortium for improving survival of
lymphoma (CISL) trial. Ann. Hematol. 94 (11), 1845–1851, http://dx.doi.org/10.
1007/s00277-015-2468-y.
errone, G., Corradini, P., 2014. Autologous stem cell transplantation for T-cell
lymphomas. Semin. Hematol. 51 (1), 59–66, http://dx.doi.org/10.1053/j.
seminhematol.2013.11.002.
errone, G., Farina, L., Corradini, P., 2013. Current state of art for transplantation
paradigms in peripheral T-cell lymphomas. Expert Rev. Hematol. 6 (4),
465–474, http://dx.doi.org/10.1586/17474086.2013.814437.
hillips, A.A., Fields, P., Hermine, O., et al., 2014. Anti-CCR4 monoclonal antibody
KW-0761 (mogamulizumab) or investigator’s choice of chemotherapy in
subjects with relapsed or refractory adult T-cell leukemia-lymphoma (ATL). J.
Clin. Oncol. 32 (Suppl. 5s), abstract TPS8622.
iekarz, R.L., Frye, R., Prince, H.M., et al., 2011. Phase 2 trial of romidepsin in
patients with peripheral T-cell lymphoma. Blood 117 (22), 5827–5834, http://
dx.doi.org/10.1182/blood-2010-10-312603.
oole, R.M., 2014. Belinostat: ﬁrst global approval. Drugs 74 (13), 1543–1554,
http://dx.doi.org/10.1007/s40265-014-0275-8.
ro, B., Advani, R., Brice, P., et al., 2012. Brentuximab vedotin (SGN-35) in patients
with relapsed or refractory systemic anaplastic large-cell lymphoma: results of
a  phase II study. J. Clin. Oncol. 30 (18), 2190–2196, http://dx.doi.org/10.1200/
JCO.2011.38.0402.
ro, B., Advani, R.H., Brice, P., et al., 2013. Three-year survival results from an
ongoing phase 2 study of brentuximab vedotin in patients with relapsed or
refractory systemic anaplastic large cell lymphoma. Blood 122 (21), abstract
1809.
ro, B., Advani, R.H., Brice, P., et al., 2014. Four-year survival data from an ongoing
pivotal phase 2 study of brentuximab vedotin in patients with relapsed or
refractory systemic anaplastic large cell lymphoma. Blood 124 (21), abstract
3095.EVLIMID® (lenalidomide) capsules, for oral us, 2015. Full prescribing information.
Revised: 9/2014. Celgene Corporation, Summit, NJ, USA (accessed 10.02.15.).
http://www.revlimid.com/wp-content/uploads/2013/11/PI.pdf.ogy/Hematology 99 (2016) 214–227
Ravandi, F., Aribi, A., O’Brien, S., et al., 2009. Phase II study of alemtuzumab in
combination with pentostatin in patients with T-cell neoplasms. J. Clin. Oncol.
27 (32), 5425–5430, http://dx.doi.org/10.1200/JCO. 2009.22.6688.
Redaelli, S., Farina, F., Stasia, A., et al., 2013. High response rates to crizotinib in
advanced, chemoresistant ALK+ lymphoma patients. Blood 122 (21), abstract
368.
Reddy, N.M., Evens, A.M., 2014. Chemotherapeutic advancements in peripheral
T-cell lymphoma. Semin. Hematol. 51 (1), 17–24, http://dx.doi.org/10.1053/j.
seminhematol.2013.11.006.
Ribrag, V., Caballero, D., Fermé, C., et al., 2013. Multicenter phase II study of
plitidepsin in patients with relapsed/refractory non-Hodgkin’s lymphoma.
Haematologica 98 (3), 357–363, http://dx.doi.org/10.3324/haematol.2012.
069757.
Sallah, S., Wan, J.Y., Nguyen, N.P., 2001. Treatment of refractory T-cell malignancies
using gemcitabine. Br. J. Haematol. 113 (1), 185–187, http://dx.doi.org/10.
1046/j.1365-2141.2001.02743.x.
Savage, K.J., Horwitz, S.M., Zinzani, P.L., et al., 2014. Safe and effective treatment of
patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) and
low baseline platelet counts with belinostat. Blood 124 (21), abstarct 3075.
Schmitz, N., Wu,  H.S., Glass, B., 2014. Allogeneic transplantation in T-cell
lymphomas. Semin. Hematol. 51 (1), 67–72, http://dx.doi.org/10.1053/j.
seminhematol.2013.11.010.
Sharaiha, R.Z., Lebwohl, B., Reimers, L., et al., 2012. Increasing incidence of
enteropathy-associated T-cell lymphoma in the United States, 1973–2008.
Cancer 118 (15), 3786–3792, http://dx.doi.org/10.1002/cncr.26700.
Shimanovsky, A., Dasanu, C.A., 2013. Pralatrexate: evaluation of clinical efﬁcacy
and toxicity in T-cell lymphoma. Expert Opin. Pharmacother. 14 (4), 515–523,
http://dx.doi.org/10.1517/14656566.2013.770474.
Siddiqi, T., Frankel, P., Ruel, C., et al., 2014. Phase 1 study of MLN8237, an aurora
kinase A (AURKA) inhibitor, combined with vorinostat, a histone deacetylase
(HDAC) inhibitor, in lymphoid malignancies. Blood 124 (21), abstract 4483.
Sirotnak, F.M., DeGraw, J.I., Colwell, W.T., et al., 1998. A new analogue of
10-deazaaminopterin with markedly enhanced curative effects against human
tumor xenografts in mice. Cancer Chemother. Pharmacol. 42 (4), 313–318,
http://dx.doi.org/10.1007/s002800050823.
Subramaniam, J.M., Whiteside, G., McKeage, K., et al., 2012. Mogamulizumab: ﬁrst
global approval. Drugs 72 (9), 1293–1298, http://dx.doi.org/10.2165/
11631090-000000000-00000.
Swerdlow, S.H., Campo, E., Harris, N.L., et al., 2008. Pathology and genetics of
tumours of hematopoietic and lymphoid tissues. In: World Health
Organization Classiﬁcation of Tumours. International Agency for Research on
Cancer Press, Lyon, France (Chapter 11) 270-299367.
TREANDATM (bendamustine HCL) injection, 2015. Full prescribing information.
Revised: 9/2013. Teva Pharmaceuticals USA, Inc., North Wales, PA, USA
(accessed 06.02.15.). http://www.treanda.com/PDF/TREANDA ﬁnal PI.pdf.
Toumishey, E., Prasad, A., Dueck, G., et al., 2015. Final report of a phase 2 clinical
trial  of lenalidomide monotherapy for patients with T-cell lymphoma. Cancer
121 (5), 716–723, http://dx.doi.org/10.1002/cncr.29103.
Velasquez, W.S., Cabanillas, F., Salvador, P., et al., 1988. Effective salvage therapy
for lymphoma with cisplatin in combination with high-dose Ara-C and
dexamethasone (DHAP). Blood 71 (1), 117–122.
Velasquez, W.S., McLaughlin, P., Tucker, S., et al., 1994. ESHAP—an effective
chemotherapy regimen in refractory and relapsing lymphoma: a 4-year
follow-up study. J. Clin. Oncol. 12 (6), 1169–1176.
Vose, J., Armitage, J., Weisenburger, D., International T-Cell Lymphoma Project,
2008. International peripheral T-cell and natural killer/T-cell lymphoma study:
pathology ﬁndings and clinical outcomes. J. Clin. Oncol. 26 (25), 4124–4130,
http://dx.doi.org/10.1200/JCO.2008.16.4558.
Wang, E.S., O’Connor, O., She, Y., et al., 2003. Activity of a novel anti-folate (PDX,
10-propargyl 10-deazaaminopterin) against human lymphoma is superior to
methotrexate and correlates with tumor RFC-1 gene expression. Leuk.
Lymphoma 44 (6), 1027–1035, http://dx.doi.org/10.1080/
1042819031000077124.
Weidmann, E., Hess, G., Chow, K.U., et al., 2010. A phase II study of alemtuzumab,
ﬂudarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral
T-cell lymphomas. Leuk. Lymphoma 51 (3), 447–455, http://dx.doi.org/10.
3109/10428190903580402.
Wilson, W.H., Bryant, G., Bates, S., et al., 1993. EPOCH chemotherapy: toxicity and
efﬁcacy in relapsed and refractory non-Hodgkin’s lymphoma. J. Clin. Oncol. 11
(8), 1573–1582.
Winkler, D.G., Faia, K.L., DiNitto, J.P., et al., 2013. PI3K- and PI3K- inhibition by
IPI-145 abrogates immune responses and suppresses activity in autoimmune
and inﬂammatory disease models. Chem. Biol. 20 (11), 1364–1374, http://dx.
doi.org/10.1016/j.chembiol.2013.09.017.
XALKORI® (crizotinib) capsules, oral, 2015. Full prescribing information. Revised:
5/2014. Pﬁzer Labs, New York City, NY, USA (accessed 06.02.15.). http://
labeling.pﬁzer.com/showlabeling.aspx?id=676.
Yamaguchi, M., Suzuki, R., Kwong, Y.L., et al., 2008. Phase I study of
dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide
(SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal
natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci. 99 (5),
1016–1020, http://dx.doi.org/10.1111/j.1349-7006.2008.00768.x.
Yamaguchi, M., Kwong, Y.L., Kim, W.S., et al., 2011. Phase II study of SMILE
chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal
natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study
 Oncol
Y
Y
Z
Z
Z
Z
Z
ZP.L. Zinzani et al. / Critical Reviews in
Group studye. J. Clin. Oncol. 29 (33), 4410–4416, http://dx.doi.org/10.1200/
JCO.2011.35.6287.
amamoto, K., Utsunomiya, A., Tobinai, K., et al., 2010. Phase I study of KW-0761, a
defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult
T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J. Clin. Oncol. 28
(9), 1591–1598, http://dx.doi.org/10.1200/JCO. 2009.25.3575.
ounes, A., Bartlett, N.L., Leonard, J.P., et al., 2010. Brentuximab vedotin (SGN-35)
for relapsed CD30-positive lymphomas. N. Engl. J. Med. 363 (19), 1812–1821,
http://dx.doi.org/10.1056/nejmoa1002965.
OLINZA® (vorinostat) Capsules, 2015. Full prescribing information. Revised:
04/2013. Patheon, Inc., Ontario, Canada (accessed 05.02.15.). http://www.
merck.com/product/usa/pi circulars/z/zolinza/zolinza pi.pdf.
elenetz, A.D., Hamlin, P., Kewalramani, T., et al., 2003. Ifosfamide, carboplatin,
etoposide (ICE)-based second-line chemotherapy for the management of
relapsed and refractory aggressive non-Hodgkin’s lymphoma. Ann. Oncol. 14,
i5–10, http://dx.doi.org/10.1093/annonc/mdg702.
inzani, P.L., Magagnoli, M.,  Bendandi, M., et al., 1998. Therapy with gemcitabine in
pretreated peripheral T-cell lymphoma patients. Ann. Oncol. 9 (12),
1351–1353.
inzani, P.L., Baliva, G., Magagnoli, M.,  et al., 2000. Gemcitabine treatment in
pretreated cutaneous T-cell lymphoma: experience in 44 patients. J. Clin.
Oncol. 18 (13), 2603–2606.
inzani, P.L., Alinari, L., Tani, M.,  et al., 2005. Preliminary observations of a phase II
study of reduced-dose alemtuzumab treatment in patients with pretreated
T-cell lymphoma. Haematologica 90 (5), 702–703.
inzani, P.L., Venturini, F., Stefoni, V., et al., 2010. Gemcitabine as single agent in
pretreated T-cell lymphoma patients: evaluation of the long-term outcome.
Ann. Oncol. 21 (4), 860–863, http://dx.doi.org/10.1093/annonc/mdp508.ogy/Hematology 99 (2016) 214–227 227
Zinzani, P.L., Pellegrini, C., Broccoli, A., et al., 2011. Lenalidomide monotherapy for
relapsed/refractory peripheral T-cell lymphoma not otherwise speciﬁed. Leuk.
Lymphoma 52 (8), 1585–1588, http://dx.doi.org/10.3109/10428194.2011.
573031.
Zinzani, P.L., Corradini, P., Gallamini, A., et al., 2012. Overview of alemtuzumab
therapy for the treatment of T-cell lymphomas. Leuk. Lymphoma 53 (5),
789–795, http://dx.doi.org/10.3109/10428194.2011.629701.
Zinzani, P.L., Coifﬁer, B., Radford, J., et al., 2014. A phase II open-label, multi-center
study of anti-CCR4 monoclonal antibody mogamulizumab (KW-0761) in
patients with previously treated peripheral T-cell lymphoma (PTCL). Blood 124
(21), abstract 1763.
Biography
Pier Luigi Zinzani is an Associate Professor of Hematology at the Institute of
Hematology ‘L. e A. Seràgnoli’ at the University of Bologna in Italy. He is a member
of  the Italian Society of Hematology, Italian Society of Experimental Hematology,
American Society of Hematology, and American Society of Clinical Oncology, and is
currently serving as President of the Fondazione Italiana Linfomi. Professor Zinzani
has presented his research at more than 220 national and international congresses,
has written more than 400 peer-reviewed articles in high-proﬁle hematology and
oncology journals, and has held the position of Associate Editor of Annals of Oncology
since January 2014. His current research projects focus on clinical trial method-
ology, new drug development, non-Hodgkin lymphoma (including exploration of
prognostic factors), Hodgkin’s disease, chronic lymphocytic leukemia, and hairy cell
leukemia.
